VOGO acts against COVID-19!

COVID-19 – VOGO participation in the development, production and distribution of a rapid saliva-based screening test

VOGO is honored to announce today, that it is collaborating with scientists from the CNRS (French National Center for Scientific Research) laboratory Sys2Diag, and with biotechnology company SkillCell for providing a rapid saliva-based screening test, if the results of the clinical trial are conclusive.

Faced with the current health crisis, it has been established that widespread rapid testing of populations would have a decisive impact. The EasyCov test has all the qualities to be able to meet this challenge.

Since April 11th, a clinical trial has been promoted by the Montpellier University Hospital with SkillCell and scientists from the CNRS laboratory Sys2Diag. If the results of the clinical trial are conclusive, an efficient and reliable development, production and distribution chain for widespread rapid testing of medical personnel could be ready as early as May…

Development of a version of Easycov for the general public is in progress. In this context, find out how the VOGO teams are acting to develop and launch the digital tool that will automate results analysis, which would be required for widespread screening of the population.

Find out all the details in theย press releaseย to this related test.

 

Category: Latest News

Share this article:

Other related articles

  • VOGOSPORT POC at Roland Garros!

    Roland Garros and its innovationsโ€ฆย โ€œย A new angle of viewย โ€ย with VOGOSPORT FAN Until October 11… For the first time, in collaboration with its partners Orange, France TV and Oppo, VOGO is setting up its VOGOSPORT solution on a 5G network, implemented on-site by Orange. Theseย innovations have been made possible atย Roland Garros 2020 tournament thanks to the…

    VOGOSPORT POC at Roland Garros!
VOGO